Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus methotrexate for recurrent or metastatic head and neck squamous cell carcinoma
NL-OMON40553Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Methotrexate with Cetuximab + methotrexate (2 arms). Primary endpoints: Dose-limiting toxicity, Toxicity and 1 more. Started Feb 2014; status: active, not recruiting.
02
Drugs
cetuximabmethotrexate
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON40553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40553.